Why Recordati’s $12.4bn takeover bid could reshape Italy’s listed pharma landscape
Recordati’s $12.4bn buyout bid tests whether rare disease growth can justify one of Europe’s biggest pharma take-private deals.
Pharma & Biotech
Pharma & Biotech
Why Sun Pharma’s $11.75bn Organon acquisition could reshape specialty pharma
Sun Pharma gets global scale with Organon. The harder test is whether women’s health, biosimilars, and debt discipline can move together.